Bank of America initiated coverage on Cepheid (NASDAQ: CPHD ) with a Buy rating and a $40 price objective. Bank of America noted, "With one of the largest available test menus and more on the way, CPHD's prospects for increasing its installed base and reagent pull-through is positive, as